The Americans have coined a term for it – the cocktail of flu, Covid and RSV. They call it the ‘tripledemic’.
Barclays Capital, tracking the experience of the US, believes this toxic combination could be a problem as we head into the winter period in the northern hemisphere.
Assessing the latest data, the investment bank’s number crunchers have surmised that current levels of flu infection are the highest since 2010 for this, the early part of the season.
hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.